Table 3 Comparisons of longitudinal changes in the limitation of extraocular movement, diplopia, clinical activity score, and thyroid status in the improved and not-improved groups.
From: Prognostic factors of restrictive myopathy in thyroid eye disease
Pre-treatment | 3 months | 6 months | 9 months | 12 months | |
|---|---|---|---|---|---|
LOM (SD) | |||||
Improved | 2.5 (1.0) | 2.2 (1.0) | 1.9 (1.1) | 1.2 (1.1)† | 1.2 (1.0)† |
Not-improved | 2.2 (1.1) | 2.4 (0.9) | 2.2 (1.1) | 2.4 (1.0)† | 2.3 (1.1)† |
Diplopia grade (SD) | |||||
Improved | 1.9 (0.9) | 1.3 (0.8)† | 1.3 (0.7)† | 1.3 (1.0)† | 1.1 (1.0)† |
Not-improved | 2.0 (0.9) | 2.2 (0.9)† | 2.1 (0.9)† | 2.2 (0.8)† | 2.1 (1.0)† |
CAS (SD) | |||||
Improved | 3.0 (1.9) | 1.3 (1.6) | 1.5 (1.5) | 1.2 (1.2) | 1.4 (1.7) |
Not-improved | 2.7 (1.6) | 1.6 (1.4) | 1.7 (1.2) | 1.7 (1.5) | 1.1 (1.4) |
TSH, μIU/mL (SD) | |||||
Improved | 2.7 (7.4) | 2.7 (7.0) | 1.8 (3.0) | 0.6 (1.0) | 3.3 (4.4) |
Not-improved | 2.5 (5.6) | 5.7 (11.6) | 4.3 (7.0) | 0.6 (0.9) | 3.6 (5.9) |
T3, ng/dL (SD) | |||||
Improved | 121.2 (40.6) | 146.1 (70.3) | 106.6 (22.8) | 111.6 (28.5) | 97.1 (19.4)† |
Not-improved | 129.5 (39.6) | 111.1 (27.7) | 120.0 (32.6) | 130.8 (38.2) | 127.1 (30.2)† |
fT4, ng/dL (SD) | |||||
Improved | 1.7 (1.6) | 1.3 (0.3) | 1.3 (0.3) | 1.3 (0.3) | 1.3 (0.6) |
Not-improved | 1.3 (0.6) | 1.1 (0.2) | 1.1 (0.2) | 2.3 (1.9) | 1.5 (0.7) |
TSAb, % (SD) | |||||
Improved | 229.3 (114.1) | NA | NA | NA | 162.5 (116.6) |
Not-improved | 345.0 (178.6) | NA | NA | NA | 266.4 (118.2) |
TSHR-Ab, IU/L (SD) | |||||
Improved | 24.3 (54.7) | 14.6 (22.9) | 6.5 (12.5) | 9.6 (12.8) | 3.2 (3.1) |
Not-improved | 24.7 (29.9) | 15.3 (26.9) | 4.7 (5.3) | 2.1 (2.0) | 7.0 (11.6) |
